Keppra and Hyponatremia
Yes, Keppra (levetiracetam) can cause hyponatremia, though it is not listed as a common adverse effect in the FDA label. The evidence shows a strong association between levetiracetam initiation and hospitalization for hyponatremia, with risk comparable to or exceeding traditional sodium-lowering antiepileptic drugs.
Evidence from Clinical Studies
The most robust evidence comes from a large population-based study showing that newly initiated levetiracetam carries a 9.76-fold increased risk of hospitalization due to hyponatremia compared to controls, which is similar to carbamazepine (9.63-fold) and higher than phenytoin (4.83-fold) or valproate (4.96-fold) 1. This contradicts the common perception that levetiracetam is free from electrolyte disturbances.
Risk Profile by Treatment Duration
- Newly initiated treatment (≤90 days): The risk is highest during this period, with an adjusted OR of 9.76 for hospitalization due to hyponatremia 1
- Ongoing treatment: The risk decreases but remains elevated at 7.97 for oxcarbazepine, though specific ongoing treatment data for levetiracetam shows lower risk than during initiation 1
Clinical Case Evidence
Multiple case reports document levetiracetam-induced hyponatremia:
- Repeated challenge cases: One patient developed hyponatremia after two separate challenges with levetiracetam, particularly in the context of predisposition to SIADH 2
- Treatment-resistant hyponatremia: A case of levetiracetam-induced hyponatremia that was resistant to tolvaptan (a vasopressin antagonist) has been reported 3
- Multifactorial cases: A patient with central diabetes insipidus developed significant hyponatremia and seizures while on levetiracetam combined with pain medications; sodium normalized after switching to lacosamide 4
FDA Label Information
The official FDA label for Keppra does not list hyponatremia as a common adverse effect 5. The most frequently reported adverse events include somnolence, asthenia, infection, dizziness, nervousness, and hostility. However, the absence from the label does not negate the clinical evidence from post-marketing surveillance and research studies.
Comparison with Other Antiepileptic Drugs
When considering alternatives for patients at risk of hyponatremia:
- Highest risk: Oxcarbazepine, carbamazepine, and levetiracetam 1
- Moderate risk: Phenytoin and valproate 1
- Lowest risk: Lamotrigine (OR 1.67) and gabapentin (OR 1.61) may be advantageous in patients at risk of developing hyponatremia 1
Clinical Management Recommendations
Monitoring Strategy
Monitor serum sodium levels closely during the first 90 days of levetiracetam initiation, as this is the highest-risk period 1. The guideline recommendation for monitoring complete blood count should be extended to include electrolytes 6.
High-Risk Populations
Be particularly vigilant in patients with:
- Pre-existing conditions predisposing to SIADH 2
- Central diabetes insipidus or other endocrine disorders 4
- Concurrent use of other medications that can cause hyponatremia (diuretics, SSRIs, NSAIDs) 4
- Heart failure patients, where hyponatremia carries high mortality 3
- Traumatic intracranial hemorrhage, though one study showed no clinically significant difference compared to phenytoin in this population 7
Dosing Considerations
Levetiracetam dosing typically ranges from 500 mg twice daily up to 1000-2000 mg daily in divided doses 6. Dose adjustments may be necessary in renal dysfunction, which itself can complicate sodium management 6.
When to Consider Alternative Agents
If hyponatremia develops on levetiracetam, consider switching to lamotrigine or lacosamide, which have lower associations with sodium disturbances 1, 4. One case report specifically documented successful resolution of hyponatremia after switching from levetiracetam to lacosamide 4.
Common Pitfalls
- Assuming levetiracetam is "safe" regarding electrolytes: The newer evidence contradicts this assumption 1
- Not monitoring sodium during initiation: The highest risk period is the first 90 days 1
- Overlooking drug interactions: Concurrent use of NSAIDs, diuretics, or other sodium-lowering medications amplifies risk 4
- Attributing hyponatremia solely to underlying disease: In patients on levetiracetam with hyponatremia, consider the medication as a contributing factor 2, 3